Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy-Reference-Cited by-同舟云学术

Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy

Published:2011-10 Issue:1 Volume:141 Page:90-102
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Jolles S.,Bernatowska E.,de Gracia J.,Borte M.,Cristea V.,Peter H.H.,Belohradsky B.H.,Wahn V.,Neufang-Hüber J.,Zenker O.,Grimbacher B.

Funder

CSL Behring AG, Berne, Switzerland

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference43 articles.

1. Primary immunodeficiency diseases due to defects in lymphocytes;Buckley;N. Engl. J. Med.,2000

2. Primary immunodeficiency diseases: an update;Chapel;Clin. Exp. Immunol.,2003

3. Common variable immunodeficiency: clinical and immunological features of 248 patients;Cunningham-Rundles;Clin. Immunol.,1999

4. Ig beta deficiency in humans;Lougaris;Curr. Opin. Allergy Clin. Immunol.,2008

5. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach;Ochs,2007

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis;Journal of Comparative Effectiveness Research;2024-09

3. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults;Journal of Clinical Immunology;2023-12-22

4. Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: A Historical Perspective;Journal of Clinical Medicine;2023-11-07

5. Inborn errors of immunity in mainland China: the past, present and future;BMJ Paediatrics Open;2023-07